论文部分内容阅读
１９８６～１９９３年对手术不能切除的肝癌４５例进行了经导管化疗栓塞（ＴＣＥ）治疗，并同肝切除及肝切除术后经导管化疗（ＴＣＴ）病例进行对比分析。ＴＣＥ治疗的抗癌药用量可达周身用药的２～３倍且副作用小。其中９０％肝癌肿块术后不同程度缩小，术后生存时间与肝切除相似。３例ＴＣＥ治疗后行肝切除，肝切除后行ＴＣＴ病例比单纯肝切除病例术后平均生存时间明显延长。提示ＴＣＥ治疗对不能切除的肝癌是一种有效的姑息治疗方法，术后行ＴＣＴ则是一种有效的辅助治疗方法。
From 1986 to 1993, transcatheter arterial chemoembolization (TCE) was performed on 45 patients with unresectable hepatocellular carcinoma, and compared with hepatectomy and transcatheter arterial (TCT) after hepatectomy. TCE treatment of anti-cancer drugs up to 2 to 3 times the body medication and side effects. Among them, 90% of liver tumors were reduced to different degrees after surgery, and the postoperative survival time was similar to that of liver resection. Three cases of TCE were treated with hepatectomy. TCT after hepatectomy was significantly longer than the average survival time after hepatectomy. It is suggested that TCE treatment is an effective palliative treatment for unresectable liver cancer. TCT after operation is an effective adjuvant therapy.